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Abstract
Amplification and/or overexpression of genes encod-
ing tyrosine kinase receptors KIT and ERBB2 have
been reported in testicular germ cell tumors (TGCTs).
These receptors can bind the adaptor molecule GRB7
encoded by a gene adjacent to ERBB2 at 17q12, a re-
gion also frequently gained in TGCTs. GRB7 binding
may be involved in the activation of RAS signaling
and KRAS2maps to 12p, which is constitutively gained
in TGCT and lies within a minimum overlapping region
of amplification at 12p11.2–12.1, a region we have pre-
viously defined. RAS proteins activate BRAF, and ac-
tivating mutations of genes encoding these proteins
have been described in various tumors. Here we de-
termine the relationships between expression levels
and activating mutations of these genes in a series of
65 primary TGCTs and 4 TCGT cell lines. High levels
of expression and activating mutations in RAS were
mutually exclusive events, and activating mutations in
RAS were only identified in the seminoma subtype. Mu-
tations in BRAF were not identified. Increased ERBB2
expression was associated with differentiated nonsemi-
noma histology excised from lymph nodes postchemo-
therapy. Mutation, elevated expression, and correlations
between expression levels ofKRAS2,GRB7, andKIT are
consistent with their involvement in the development
of TGCTs.
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Introduction
Testicular germ cell tumors (TGCTs) of adolescents and
adults are the most common tumors in young men [1]. They
are classified into twomain histologic categories: seminoma
(SE) and nonseminoma (NSE). SE resemble primordial
germ cells, and NSE are composed of neoplastic tissues ex-
hibiting either somatic, embryonal, or extraembryonal tis-
sues [1]. Primordial germ cells are generally considered as
the cells of origin of TGCT and are believed to give rise to
carcinoma in situ (CIS), which is also known as intratubular
germ cell neoplasia—a precursor lesion of both SE andNSE [2].
TGCTs consistently show gain of the short arm of chro-
mosome 12 [3], and we have previously mapped a minimum
overlapping region of gain at 12p11.2–p12.1 [4]. This region in-
cludes the KRAS2 gene, although one case with amplification
of the region that does not include KRAS2 is reported [5]. RAS
has a significant role in normal germ cell development, affect-
ing proliferation and migration [6]. A high expression of KRAS2
has been reported in a small number of TGCT samples and
cell lines, and activating mutations in RAS genes have been
described in 10% to 40%; a review of the literature in 1995
determined the overall frequency at 10% [7–9]. Activating mu-
tations or enhanced expressions of normal RAS genes are
established enough to transform NIH3T3 cells and have been
associated with many tumor types [10,11].
RAS activation can result in signaling through the RAS/RAF/
MEK/ERK/MAP kinase pathway. Activation of ERK through
phosphorylation has been recently reported in the majority
of SE and NSE [9]. Activating mutations of BRAF have been
identified in a wide range of tumors, including melanoma and
colorectal neoplasms [12,13]. Activating mutations of BRAF
also have the ability to transform NIH3T3 cells, and cell lines
do not necessarily require RAS coactivation, suggesting func-
tional redundancy in some tumor types [12]. However, the
mutual exclusivity of activating mutations in RAS and BRAF
is not the case in all tumors, and BRAF mutations have been
found in pancreatic cancers with KRAS2 codon 12 mutations
[14]. The MAP kinase pathway could therefore be affected by
BRAF mutations in addition to other mechanisms and may
potentially be involved in the pathogenesis of TGCT.
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KIT and ERBB2 are receptor tyrosine kinases that are
known to activate the RAS signaling cascade [15,16].We have
recently identified gain in the copy number of a small region at
4q12, and we have shown that KIT is the only gene amplified
from this region in some cases [17] (McIntyre, submitted for
publication). Specific amplification and previously described
activating mutations for KIT suggest a role for this gene prod-
uct in the development of TGCT [18,19]. ERBB2 maps to a
region of recurrent gain at 17q12 in TGCTs (http://www.cgap.
nci.nih.gov/Chromosomes/Mitelman; http://www.helsinki.fi/
cmg/cgh_data.html); in one study, increased expression has
been associated with adverse clinical outcomes in NSE [20].
GRB7 also maps to 17q12 and has been shown to be
overexpressed in some TGCTs [21,22]. GRB7 is an adapter
molecule that can bind directly to KIT and ERBB2 through
its SH2 domain [23] and is also proposed to bind directly to
RAS through its RAS association domain. In this way, GRB7
may have an important role in the regulation of the down-
streamsignaling of these kinases. Furthermore,GRB7 is also
known to play a role in cell migration [23].
The genomic alterations in TGCT described above and
the potential functional links and roles for candidate genes
from these regions prompted us to further investigate these
genes in TGCTs. Here we have examined the copy number
of KRAS2 in CIS adjacent to a tumor shown to have am-
plification of this gene and to have screened for activating
BRAF mutations in TGCTs. Through analysis of a large
number of samples, we have demonstrated the relation-
ships between activating mutations, copy numbers, and ex-
pression levels of KRAS2, KIT, ERBB2, and GRB7, which
are indicative of their involvement in the cellular behavior
of TGCTs.
Materials and Methods
Tumor Samples
Snap-frozen primary tumor samples histologically veri-
fied as SE (32), NSE (27), and combined tumors (6) were
all collected through the Royal Marsden Hospital NHS
Trust. Six single samples (SE, five; NSE, one) were obtained
from patients with sporadic bilateral disease, and two fur-
ther cases of SE had a family history of TGCT. Patient con-
sent and ethical approval were obtained for the use of this
material in the study, in accordance with the tenets of the
Helsinki Declaration. The cell lines Tera1, Tera2, GCT27,
GCT44, HT-29, Colo205, and MAWI were cultured as de-
scribed in Summersgill et al. [24] and ATCC (Manassas,
VA; http://www.atcc.org). Genomic DNA was prepared
using standard procedures, and RNA was extracted using
Trizol, in accordance with the manufacturer’s instructions
(Life Technologies, Grand Island, NY). Commercially avail-
able normal pooled testis tissues from 45 samples were
used as controls in expression experiments (BD Biosci-
ences, Palo Alto, CA). CIS and corresponding tumor tissues
from three samples were microdissected from Bouins-fixed
paraffin-embedded tissues, and DNA was extracted as pre-
viously described [25].
Mutation Analysis of KRAS and NRAS
DNA from cell lines with known activating mutations of
KRAS and NRAS at codons 12, 13, and 61 were used as
controls. These and the test samples were screened by se-
quencing exons 2 and 3 of both genes [8]. The primers used
to amplify the sequence of interest were as follows: KRAS2
exon 2: forward 5V-TTAACCTTATGTGTGACATGTTCTAA-
3V, reverse 5V-CCTTTATCTGTATCAAAGAATGGTC-3V;
KRAS2 exon 3: forward 5V-TCTTTGGAGCAGGAACAATG-
3V, reverse 5V-TGCATGGCATTAGCAAAGAC-3V;NRAS exon
2: forward 5V-GGGTTTTCATTTCCATTGATT-3V, reverse 5V-
ATTCTTTATACAGAATATGGGTAAA-3V; NRAS exon 3: for-
ward 5V-GGCAGAAATGGGCTTGAATA-3V, reverse 5V-
AAGCTCTATCTTCCCTAGTGTGGT-3V. Polymerase chain
reaction (PCR) products were bidirectionally screened by
direct sequence analysis on an ABI3100 sequencer using
the ABI PRISMBigDye Terminator v3.1 Cycle Sequencing Kit
(Applied Biosystems, Foster City, CA). Mutations were con-
firmed by repeat sequencing analysis from an independently
amplified reaction. Negative controls (no DNA) and normal
controls (pooled normal DNA) were included in every set of
amplification and sequencing analysis.
Mutation Analysis of BRAF
DNA from cell lines HT-29, Colo205, andMAWIwith known
activating mutations of BRAF in exon 11 at G1403C (G468A)
and in exon 15 at T1796A (S599E) and C1786G (L596V) were
used as controls [12]. These and the TGCT samples were
screened by conformational sensitive gel electrophoresis
(CSGE). Exon 11 was amplified using the forward primer 5V-
TTGGCTTGACTTGACTTT-3V and the reverse primer 5V-
ATCCTATTATGACTTGTC-3V. Exon 15 was amplified using
the forward primer 5V-TTCATAATGCTTGCTCTGATAGG-3V
and the reverse primer 5V-TGTGAATACTGGGAACTAT-
GAAAA-3V. Primers were 5V-end–labeled with 32P. DNA were
amplified in 20-ml PCR reactions of 30 seconds at 94jC;
30 seconds at 68jC to 50jC touchdown and 55jC, respec-
tively; followed by 1 minute at 72jC for 30 cycles. In exon 15,
the positive control cell lines HT-29, Colo205, and MAWI
were used and were consistently positive. The products were
resolved on a 6% acrylamide gel under semidenaturing con-
ditions. No positive controls were available for exon 11; there-
fore, 4 of 65 random samples were also sequenced. PCR
products were bidirectionally screened by direct sequence
analysis on an ABI3100 sequencer using the ABI PRISM
BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Bio-
systems). Negative controls (no DNA) and normal controls
(pooled normal DNA) were included in every set of amplifica-
tion and CSGE and sequencing analyses.
Quantitative PCR Analyses
Quantitative PCR and reverse transcription (RT)–PCR
were performed using the ABI PRISM 7700 Sequence
Detection System, in accordance with the manufacturer’s
instructions (Applied Biosystems). B2-microglobulin (B2M)
was used as endogenous control in expression studies,
whereas POLR2D at 2q21 was used as endogenous control
in genomic studies as this region rarely shows loss or gain
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in samples according to reported karyotype and comparative
genomic hybridization (CGH) analyses (http://www cgap.
nci.nih.gov/Chromosomes/Mitelman; http://www.helsinki.
fi/cmg/cgh_data.html). Expression data were normalized to
pooled normal testis RNA, and genomic data were normal-
ized to normal male DNA. Primer and probe sets for the
genes GRB7, ERBB2, and the control B2M were purchased
from Applied Biosystems (assays Hs00180450, Hs00170433,
and Hs99999907). Primers and probes designed for genomic
analysis ofPOLR2D (chromosome 2 control),KRAS2, and ex-
pression analysis of KRAS2 were as follows: RBP4: forward
5V-CCCAGGTGACATGGAATCTTG-3V, probe 5V-AGCCTTG-
TGCAGTGGCAGCCAGT-3V, reverse 5V-GCAGAGGCACG-
TTCAGGAA-3V; KRAS2 genomic: forward 5V-TCTCGAC-
ACAGCAGGTCAAGA-3V, probe 5V-AGTACAGTGCAATG-
AGGGACCAGTACATGAGG-3V, reverse 5V-CTTCAAATG-
ATTTAGTATTATTTATGGCAAAT-3V; KRAS2 expression:
forward, probe, reverse. Both the B2M and POLR2D control
used were Vic-labeled. All test sets were labeled with Fam.
Quantification of each sample was determined by averaging
the results from three separate reactions.
Results
Mutation Analysis of KRAS2, NRAS, and BRAF
Activating mutations in codons 12 and 13 of KRAS2 and
NRAS were identified through direct sequencing in four and
one primary tumor samples, respectively (8% of all TGCTs).
The four KRAS2 mutations were as follows: two G12V, one
G12C, and one G13N. TheNRASmutation was G12V. All five
mutations were determined in primary tumors of the SE sub-
type (16%). No activating RAS mutations were determined in
the NSE primary tumors or cell lines. No mutations of BRAF
were detected in any of the TGCT primary samples or cell
lines. An example of these results can be seen in Figure 1.
Quantitative PCR Analyses
Using quantitative techniques, we determined the copy
number and expression levels of KRAS2 and the expression
of ERBB2 andGRB7 in the 65 primary TGCTand 4 cell lines.
KRAS2 copy number was increased in all cases, in keeping
with the gain of 12p found in all TGCTs. However, KRAS2
copy number was not increased in CIS (Figure 2), which was
microdissected as previously described [25]. Twenty-eight
percent of SE, 50% of combined tumors, 39% of NS, and all
the cell lines showed an increased expression of KRAS2,
which was two-fold greater than that of normal testis control
(Figure 3). KRAS2 expression in normal testis was greater
than in any normal tissue examined, with an expression level
that was 5.5-fold greater than the average of a range of 17
other normal tissues examined. Increased expressions of
KRAS2 and activating RAS mutations were mutually exclu-
sive events in the samples analyzed here. A significant posi-
tive correlation was determined between the genomic copy
number and the expression of KRAS2 in TGCTs (q = 0.456,
P < .01, n = 65).
Increased levels of GRB7 expression levels relative to
testis were noted in 63% of primary tumor samples and in cell
lines showing an expression ratio greater than two-fold that
of normal testis. Seven primary tumor samples (NSE, five;
SE, two) and all four cell lines showed an increased expres-
sion of ERBB2 greater than two-fold. All five NSE cases
with high expression of ERBB2 were cases wherein the ma-
terial was from extragonadal sites retrieved postchemother-
apy with differentiated teratoma histology. The two SE cases
with increased ERBB2 expression were both primary site
tumors associated with no known metastasis or relapse. The
expression levels quantified for KRAS2, ERBB2, and GRB7
and our previously reported results for KIT [26] were com-
pared to examine correlations in their expression patterns.
In SE, a significant positive correlation was determined
between the expression of three genes: KIT and KRAS2
(q = 0.569, P < .01, n = 32), KIT and GRB7 (q = 0.632, P <
.01, n = 37), and KRAS2 and GRB7 (q = 0.726, P < .01, n =
32). In NS, a significant positive correlation was determined
between the expression of KRAS2 and GRB7 (q = 0.712,
P < .01, n = 33), but not between KIT and GRB7 (q = 0.311,
P = .078, n = 32) (examples of correlations can be seen in
Figure 1. BRAF CSGE mutation screen. The results shown are a
representation of the 65 primary tumor samples and the 4 cell lines screened.
The results show no double-band products, which would indicate the pres-
ence of a mutation, in any sample except in the exon 15–positive control. (A)
Exon 15 results. (B) Exon 11 results.
Figure 2. KRAS2 copy number data for CIS adjacent to tumor. Dark bars
represent the copy number ratio in CIS adjacent to invasive tumor; lighter
bars denote copy number ratios of the tumor.
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Figure 4). ERBB2 expression did not correlate with the
expression of the other genes studied here.
Discussion
Mutation, increased copy number, and overexpression of
genes are associated with malignant phenotypes. Pre-
vious definition of minimum overlapping regions of gain at
12p11.2–12.1and4q12 and reports of gain at 17q12 inTGCTs
encompass the genes KRAS2, KIT, ERBB2, and GRB7 as
candidates for involvement in the development of TGCTs.
[4,17,21,22]. The relationships between mutation status and/
or expression levels of these genes and BRAF have been
determined here in a series of 65 primary TGCTsamples and
4 NSE cell lines in the light of their genomic positions and
known functional interactions.
The copy number analysis of KRAS2 that maps to 12p
did not identify copy number gain in the precursor lesion
CIS, whereas KRAS2 copy number increase was found in
all TGCT tumor samples. This is in keeping with previous
CGH analyses that did not show 12p gains in CIS adja-
cent to the tumor [25]. These data are consistent with an
increased copy number of KRAS2/12p being involved in
tumor progression [25,27,28]. A positive correlation was
determined between KRAS2 copy number and level of
expression; therefore, a gain in the region is associated
with an increased expression of KRAS2. Increased expres-
sion of wild-type RAS will transform NIH3T3 cells [10,11].
It is therefore possible that increased expression of KRAS2
activates RAS signaling in 35% of TGCTs, and activat-
ing mutations of RAS are found in a further 8% of the
TGCTs. Activating RAS mutations were confined to the SE
subtype here, although they have previously been reported
in NSE [7–9]. No increased expression of KRAS2 was
identified in the five samples with activating RAS mutations.
Therefore, activation of RAS through either overexpression
or mutation may be important in the progression from CIS
to TGCT.
Activating mutations of BRAF can also transform NIH3T3
cells, and cell lines with an activating mutation of BRAF
do not require RAS activation, suggesting functional re-
dundancy in some tumor types [12]. Here we sought to de-
termine whether activating mutations of BRAF were present
in TGCTs, particularly in samples without overexpression
or mutation of RAS. No BRAF mutations were identified,
consistent with the results of a previous study that included
six TGCT cell lines [12]. Recently, activating BRAF muta-
tions have been found within the embryonal carcinoma com-
ponent of 9% of NSE samples, although we did not look
specifically at individual NSE components in this study [9].
Figure 3. Copy number and expression ratios for KRAS2 in TGCTs. Dark bars represent the copy number ratio of tumor samples and cell lines; lighter bars denote
corresponding expression ratios. Samples with activating mutations in KRAS2 or NRAS are indicated with arrows.
Figure 4. Examples of correlations between gene expression levels in TGCT. (A) Correlation between log 2 ratio expression levels of KIT and GRB7 in SE (q =
0.632, P < .01, n = 31). (B) Correlation between log 2 ratio expression levels of KRAS2 and GRB7 in NS (q = 0.712, P < .01, n = 33).
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Increased expression of ERBB2 is associated with other
types of malignancy, including breast carcinoma, where it is
known to increase the activation of RAS signaling through its
association with GRB2 and SOS [16]. GRB7 is also known to
bind directly to both ERBB2 and KIT and is proposed also to
bind toRASproteins through its RASassociation domain. Here
we found increased expression of ERBB2 only in NSEs of
differentiated teratoma histology, excised from the lymph
nodes postchemotherapy. This is consistent with another study
demonstrating an increased expression ofERBB2 by immuno-
histochemistry in differentiated NSEs and highlighting an asso-
ciation with adverse clinical outcome [20]. In addition, we found
increased expression levels in two SE samples with localized
disease. All the cell lines derived from NSE had increased
expression of ERBB2. There is no difference in expression
between the cell lineGCT27 and its clonally selected derivative
GCT27R, which is resistant to cisplatin. Further molecular
studies are required to elucidate the association between
adverse clinical outcome and increased ERBB2 expression.
GRB7 is known to have a role in cell migration through its
association with EPHB1 and is proposed to modulate the
pattern of RAS signaling [23]. Greater-than-two-fold expres-
sion levels ofGRB7 relative to normal testis were noted in 63%
of primary tumor samples and in cell lines. This is consistent
with previous work showing increased GRB7RNA and protein
in TGCTs [21,22]. No distinct pattern of phosphorylation of
MAPK, STAT3, or AKT has been found in cases with or with-
out activating KIT mutations, and activated ERK has been re-
cently been reported in almost all SEs and NSEs [9,18].
A significant correlation between expressions of genes
encoding interacting proteins has been shown for lower organ-
isms and has been recently demonstrated for Homo sapiens
[29]. The correlations between expression levels in the tumors
examined in this study indicate interactions between KIT,
KRAS2, and GRB7 in SE and only between KRAS2 and
GRB7 in NSE, where KIT is rarely overexpressed. Gain of
KRAS2 and specific amplification of KIT, in combination with
coordinated patterns of mutation and expression of KRAS2,
KIT, and GRB7 genes, imply their involvement in TGCT
development, particularly the involvement of KIT in SE. This
may maintain or reestablish in TGCT the migratory and pro-
liferative behavior of primordial germ cells, which has been
shown to involve KIT and RAS activation in mice [30] .
The implication of KIT, ERBB2, RAS, or GRB7 in TGCTs
and the further unraveling of the signaling involved should
provide specific points at which therapies could be tar-
geted [31–33].
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